PT - JOURNAL ARTICLE AU - Kazuko Yamamoto AU - Naoki Hosogaya AU - Tsuyoshi Inoue AU - Kenta Jounai AU - Ryohei Tsuji AU - Daisuke Fujiwara AU - Katsunori Yanagihara AU - Koichi Izumikawa AU - Hiroshi Mukae TI - Efficacy of <em>Lactococcus lactis</em> strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease 2019 (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study) AID - 10.1101/2022.02.13.22270913 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.13.22270913 4099 - http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270913.short 4100 - http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270913.full AB - Introduction The coronavirus disease 2019 (COVID-19) pandemic has been a major concern worldwide; however, easily accessible treatment options for patients with mild COVID-19 remains limited. Since oral intake of Lactococcus lactis strain Plasma (LC-Plasma) enhances both the innate and acquired immune systems through activation of plasmacytoid dendritic cells (pDCs), we hypothesized that the oral intake of LC-Plasma could aid the relief or prevention of symptoms in patients with asymptomatic or mild COVID-19.Methods and analysis This is an exploratory, multicenter, double-blind, randomized, placebo-controlled trial. This study was initiated in December 2021 and concludes in April 2023. The planned number of enrolled subjects is 100 (50 patients × 2 groups); subject enrolment will be conducted until October 2022. Patients with asymptomatic or mild COVID-19 will be enrolled and randomly assigned in a 1:1 ratio to Group A (oral intake of LC-Plasma-containing capsule, 200 mg/day, for 14 days) or Group B (oral intake of placebo capsule, for 14 days). The primary endpoint is the change in subjective symptoms measured by the severity score. Secondary endpoints include SARS-CoV-2 viral loads, biomarkers for pDC activation, serum SARS-CoV-2-specific antibodies, serum cytokines, interferon and interferon-inducible antiviral effectors, and the proportion of subjects with emergency room visits to medical institutions or who are hospitalized.Ethics and dissemination The study protocol was approved by the Clinical Research Review Board of Nagasaki University, in accordance with the Clinical Trials Act of Japan. The study will be conducted in accordance with the Declaration of Helsinki, Clinical Trials Act, and other current legal regulations in Japan. Written informed consent will be obtained from all participants. The results of this study will be reported in journal publications.Registration This study was registered in the Japan Registry of Clinical Trials (registration number: jRCTs071210097).Strengths and limitations of this studyThis is the first randomized controlled trial to assess the efficacy of Lactococcus lactis strain Plasma (LC-Plasma) in preventing the onset and attenuation of symptoms in patients with asymptomatic or mild COVID-19.This study is also the first to evaluate the significance of pDC-related immune responses, including interferon production, clearance of symptoms, and prevention of COVID-19 progression.The results of this study may contribute to the development of novel treatment options for asymptomatic or mild COVID-19 patients.This is an exploratory study, due to the lack of previous clinical evidence that evaluated the effect of LC-Plasma intake in patients with COVID-19.Other limitations include the subjective endpoint as the primary endpoint and generalizability, since this study will be conducted only in Japan in Japanese patients.Competing Interest StatementKazuko Yamamoto received a research fund from Kirin Holdings Co., Ltd. for this study and another research grant from Fisher &amp; Paykel Healthcare Ltd. Tsuyoshi Inoue received research funds from Kirin Holdings Co., Ltd. for this study, and he belonged to a donated course from Kyowa Kirin Co., Ltd. Kenta Jounai, Ryohei Tsuji, and Daisuke Fujiwara are employees of Kirin Holdings Co. Ltd. Koichi Izumikawa received a research grant from Kirin Holdings Co., Ltd., for this study. Hiroshi Mukae received a research grant from Taisho Pharmaceutical Co. Ltd. All funding agencies, except Kirin Holdings Co., Ltd., played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors have no conflicts of interest to declare.Clinical TrialjRCTs071210097Funding StatementThe study is funded by Kirin Holdings Co., Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical Research Review Board of Nagasaki University gave ethical approval for this study in November, 2021 (approval number: CRB20-027).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets generated and/or analyzed during this study will not be publicly available because of the absence of a statement in the study protocol and the informed consent documents enabling data sharing with a third party after the end of the study. Data sharing has not been approved by the certified review board.